RE:RE:RE:RE:RE:N-803 had been granted Breakthrough designation. We will too FGPStock ... I just go head-to-head with you because you lack judgment and lack respect for those that try something good that could positively benefit many.
You also post on things you're not even to keep yourself up to date (*1).
And again, show us how TLT's management is way more overpaid versus other biotechs versus where we could land. Just for fun.
You over-invested in TLT as per your own statement and come here whining. Suddenly, you choke under pressure and others have to manage your bad temper and pathetic posts?
*1: you recently whined while not even being on-page, while not even being able to keep up to pace, not even knowing that things had been evolving over time:
ScienceFirst - (
9/7/2022 8:38:31 PM)
RE:RE:BreakThrough Designation ("BTD")
Late November to mid-December should be the 450-day of patient #25.
Urologist must submit its report with all the exam and document so they can be included in the "portfolio" that TLT will submit to the FDA.
So it's fair to assume that the CRO has collected all these documents for many patients so far, as they reached their 450-day milestone.
ScienceFirst - (
10/9/2022 11:04:50 AM)
2nd PP: Expected to close around Oct. 14
Closing of the financing is intended to occur on or about October 14, 2022.
It's also been clever that the first pp (closed Sept. 22) was done separately so we can notice that management participated in it and increased its participation in the company, on top of the May 14 warrants conversion. It sends a powerful (and no-brainer) signal, 45% into a pivotal NMIBC Ph. 2, within reach at being able to applyfor Breakthrough designation (patient #25 450-days milestone should be by mid-December at the latest), and with more anti-virus insights from the Head, High Containment Respiratory Virus Group, Special Pathogens, PHAC (Canada's only Lab-4 (located in Winnipeg), famoulsy known for having developed the 100% efficacy Ebola vaccine).
ScienceFirst - (
10/24/2022 7:51:10 PM)
Breakthrough designation granting is inevitable
It's pretty obvious that, after Ph. 1b p#5-6 have reached their 2y+ mark of being cancer free back in August 2021with a single dose, TLT met with the FDA and received guidances about what would be the criterias that would qualify them for the Breakthrough designation. That's why the TLT's corporate presentation was then updated on Feb. 7 2022 (at the time of excellent news on the COVID-19 news from NML's Dr. Kobasa) to include Breakthrough designation application for NMIBC to around Dec. 2022 (projected) and commercial revenues (projected) early 2023 (only Accelerated Approval program can allow for revenues).